Clinical Trial: Venetoclax, Chidamide, and Chiglitazar Sodium (VCC) in Patients With Relapsed/Refractory Acute Myeloid Leukemia

U.S., Aug. 25 -- ClinicalTrials.gov registry received information related to the study (NCT07783100) titled 'Venetoclax, Chidamide, and Chiglitazar Sodium (VCC) in Patients With Relapsed/Refractory Acute Myeloid Leukemia' on Aug. 20.

Brief Summary: To evaluate the efficacy and safety of venetoclax, chidamide, and chiglitazar sodium (VCC) in patients with relapsed or refractory acute myeloid leukemia (R/R AML).

Study Start Date: Nov. 11, 2026

Study Type: INTERVENTIONAL

Condition: Relapsed or Refractory Acute Myeloid Leukemia

Intervention: DRUG: venetoclax, chidamide, and chiglitazar sodium (VCC)

Participants will receive oral chidamide 30 mg twice weekly for 2 weeks, venetoclax 200 mg once daily for 2 weeks, and chiglitazar sodium 48...